Press release
Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments
Total revenues, which consist of net product revenues and collaboration revenues, for the first quarter 2022 totaled $210.8 million Net product revenues for
About this update from Sarepta Therapeutics, Inc.
[{"type":"text","content":"Total revenues, which consist of net product revenues and collaboration revenues, for the first quarter 2022 totaled $210.8 million Net product revenues for the first quarter 2022 totaled $188.8 million, a 51% increase over the same quarter of prior year CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2022. “We are pleased to report yet another consistent quarter of strong revenue growth for our three approved therapies – EXONDYS 51, VYONDYS 53 and AMONDYS 45 – achieving total revenue of $210.8 million dollars and net product revenues approaching $190 million. Our net product revenue performance represents a growth rate of over 50% as compared to the same quarter last year. The AMONDYS 45 launch continues to excel, and each of our three approved therapies – EXONDYS 51, VYONDYS 53 and AMONDYS 45 – contributed to our exceptional growth rate,” said Doug Ingram, Sarepta’s president and CEO. Mr. Ingram continued, “Sarepta is well positioned to thrive, largely agnostic to the challenging external market environment. We are advancing our significant multi-platform pipeline, with strong positive readouts across platforms, and we continue to enroll and dose patients in our global phase 3 pivotal studies for our lead gene therapy candidate, the EMBARK study for SRP-9001, and our lead next-generation RNA therapy, the MOMENTUM study for our PPMO SRP-5051. In addition to our strong revenue performance, we exited the first quarter with over $2 billion on our balance sheet to invest in bringing a better life to the patient communities we serve.” First Quarter 2022 Developments: Sarepta presented new data at the 2022 Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference: In March 2022, the Company had three podium and 10 poster presentations at MDA. Highlights of which included new data from the two dose cohorts in Study SRP-9003-101 evaluating SRP-9003 (rAAVrh74.MHCK7.hSGCB), Sarepta’s gene therapy for the treatment of limb-girdle muscular dystrophy Type 2E (LGMD2E); and the full results from EXPLORE DMD, a study to assess the rate of pre-existing antibodies to the rAAVrh74 vector in individuals with Duchenne muscular dystrophy (DMD). For Study SRP-9003-101, Sar...